Abstract：
OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed data from 350 patients who were enrolled from 1996-2004 in the French ANRS PRIMO Cohort or in the ANRS Resistance Group and treated with HAART during PHI. During the study period, HAART was initiated before the result of the genotypic resistance test was available. We compared patients infected with a virus resistant to > or = 1 drug of their regimen (GR group, n = 46) with patients harbouring a wild-type virus (WT group, n = 304). Virological and immunological response to treatment according to drug-resistance profile was analysed 3 months and 6 months after HAART initiation. RESULTS:In GR and WT groups, HIV RNA level was < 400 copies/ml in 68% and 83% (P = 0.02) and < 50 copies/ml in 23% and 40% (P = 0.08) 3 months after HAART initiation. In multivariable logistic regression taking into account gender, age, boosted PI regimen, plasma HIV RNA and CD4+ T-cell count at HAART initiation, patients with virus resistant to > or = 1 drug of their regimen were significantly less likely to achieve undetectable viral load at month 3 (odds ratio 0.32, 95% confidence interval 0.15-0.72) than the others. This difference was sustained up to month 6. CONCLUSION:In this large cohort of HAART-treated PHI-patients, the presence of drug resistance mutations led to suboptimal response to early therapy.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANRsubject
Has Abstractpub_date
2007-01-01 00:00:00pages
1305-10issue
8eissn
1359-6535issn
2040-2058journal_volume
12pub_type
杂志文章abstract：:Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study o...
journal_title：Antiviral therapy
pub_type： 评论,杂志文章
doi：10.3851/IMP1787
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2411
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究
doi：
更新日期：2006-01-01 00:00:00
abstract：:Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3313
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1753
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). METHODS:A total of 272 antiretroviral-naive patients with a CD4+ T-cell count of 200-350 cells/mm3 were treated wit...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究,随机对照试验
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2326
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2570
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1558
更新日期：2010-01-01 00:00:00
abstract：:P-glycoprotein (P-gp) limits bioavailability and accumulation of HIV protease inhibitors (PIs). PIs are ligands for the pregnane-X-receptor (PXR), which regulates P-gp expression. This occurs when ligands activate the receptor, initiating binding to response elements in the MDR1 promoter. PXR also activates cytochrome...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2004-10-01 00:00:00
abstract：BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:In countries where antiretroviral therapy has been available or is being rapidly expanded, the World Health Organization (WHO) recommends surveillance for transmitted HIV drug resistance (HIVDR) by threshold surveillance methods using specimens from antenatal clinics or voluntary counselling and testing (VCT...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3148
更新日期：2017-01-01 00:00:00
abstract：BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:In vitro studies have reported controversial effects of protease inhibitors (PIs) on mitochondrially driven apoptosis. Additionally, since PIs in the clinical setting are almost always given in combination with nucleoside analogues, which may have negative effects on mitochondrial DNA (mtDNA), the impact of ...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究
doi：10.3851/IMP1532
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:CD4(+) T-cell count recovery after antiretroviral therapy (ART) initiation is associated with improved health outcomes. It is unknown how the CD4(+) T-cell counts of African HIV patients recover following ART initiation. METHODS:We examined CD4(+) T-cell count recovery in a large cohort of HIV-positive pati...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2670
更新日期：2014-01-01 00:00:00
abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP2425
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP3188
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3362
更新日期：2020-06-04 00:00:00
abstract：BACKGROUND:There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B. METHODS:We determined the cumulative virological, serological and biochemical outcomes of 165 lamivudine-resistant chronic hepatitis B patients on la...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2335
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：10.3851/IMP1780
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3172
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3358
更新日期：2020-01-01 00:00:00
abstract：:HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several princi...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2000-03-01 00:00:00
abstract：BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP2938
更新日期：2015-01-01 00:00:00
abstract：:We report the first two paediatric cases of sofosbuvir treatment during high-intensity myeloablative conditioning and engraftment phases of haematopoietic stem cell transplantation. These reports highlight the safety of sofosbuvir during all phases of transplantation and the lack of interaction between sofosbuvir and ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3332
更新日期：2019-01-01 00:00:00
